HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...
Chronic Pain Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the Domain
Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...
FDA approves new type of nonopioid painkiller for acute pain
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...
Targeted Oncology15h
Exploring Zoldonrasib, Pan-RAS Inhibitors, and Future KRAS Therapies
Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
BALTIMORE, MD / ACCESS Newswire / January 30, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published ...
appliedclinicaltrialsonline20h
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...
GlobalData on MSN22h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
MindMed launches phase 3 trial for anxiety treatment
The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...
FY2024 Earnings Forecast for Adagene Issued By HC Wainwright
Investment analysts at HC Wainwright upped their FY2024 EPS estimates for Adagene in a research note issued on Monday, January 27th. HC Wainwright analyst A. He now forecasts that the company will ...
How UCLA Health’s Legacy of Theranostics Innovation Transforms Cancer Care
UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...
What is HC Wainwright’s Estimate for SGMO FY2024 Earnings?
HC Wainwright decreased their FY2024 EPS estimates for shares of Sangamo Therapeutics in a research note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now expects that ...
Sanofi: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...